← Search & browse all drugs
ALIMENTARY TRACT AND METABOLISM › DRUGS USED IN DIABETES › BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS › Other blood glucose lowering drugs, excl. insulins
dorzagliatin
A10BX18
Adult Dosing
- 75 mg orally twice daily
- Administered preprandially (within 1 hour before meals)
Pediatric Dosing
- Safety and efficacy in pediatric patients (< 18 years of age) have not been established
Indications
- Treatment of type 2 diabetes mellitus as monotherapy or in combination with metformin
Mechanism of Action
- Glucokinase activator (GKA)
- Acts on pancreatic beta cells, enteroendocrine cells, and hepatocytes to restore glucose sensing and stimulate glucose-dependent insulin secretion
Contraindications
- Hypersensitivity to dorzagliatin or any excipient
- Type 1 diabetes mellitus
- Diabetic ketoacidosis
- Severe renal impairment (eGFR < 30 mL/min/1.73m²)
Adverse Reactions
- Hypoglycemia
- Hyperuricemia
- Elevated liver enzymes (ALT/AST elevations)
- Nausea
- Upper respiratory tract infection
Drug Interactions
- Strong CYP3A4 inhibitors may increase systemic exposure of dorzagliatin
- Strong CYP3A4 inducers may decrease efficacy of dorzagliatin
- Concomitant use with other insulin secretagogues (e.g., sulfonylureas) may increase hypoglycemia risk
Curated Content: Needs Vetting Before Put to Clinical Use